Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker with very high beta-1 selectivity, listed in Japanese Guidelines for AFib management as potential option for rate control of patient with heart failure. Landiolol is now available in Europe with indication of controlling heart rate in AFib and supraventricular tachycardia. This review discusses existing clinical data in Japan and perspectives of landiolol use for acute rate control of AFib patients with cardiac dysfunction.

Department of Anaesthesia and Critical Care Medicine Cardiothoracic and Vascular Anaesthesia Azienda Ospedaliero Universitaria Pisana Via Roma n 67 Pisa Italy

Department of Cardiology and Pneumology University of Göttingen Medical Center Robert Koch Strasse 40 Göttingen Germany

Department of Cardiology Rhythmology and Intensive Care Medicine Klinikum Gütersloh Germany

Department of Clinical Research and Pharmaceutical Development Amomed Pharma GmbH Vienna Austria

Department of Internal Medicine Cardiovascular Medicine General Teaching Hospital and 1st Faculty of Medicine Charles University U Nemocnice 2 Praha 2 Prague Czech Republic

Zobrazit více v PubMed

Nieuwlaat R, Eurlings LW, Cleland JG, Cobbe SM, Vardas PE, Capucci A, López-Sendòn JL, Meeder JG, Pinto YM, Crijns HJ.. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009;53:1690–1698. PubMed

Li SJ, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M, Fu M.. Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. Circ Heart Fail 2015;8:871–879. PubMed

Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skjøth F, Lip GY.. β-Blockers in atrial fibrillation patients with or without heart failure: association with mortality in a Nationwide Cohort Study. Circ Heart Fail 2016;9:e002597.. PubMed

Bajaj NS, Bhatia V, Sanam K, Ather S, Hashim T, Morgan C, Fonarow GC, Nanda NC, Prabhu SD, Adamopoulos C, Kheirbek R, Aronow WS, Fletcher RD, Anker SD, Ahmed A, Deedwania P.. Impact of atrial fibrillation and heart failure, independent of each other and in combination, on mortality in community-dwelling older adults. Am J Cardiol 2014;114:909–913. PubMed

Arrigo M, Gayat E, Parenica J, Ishihara S, Zhang J, Choi DJ, Park JJ, Alhabib KF, Sato N, Miro O, Maggioni AP, Zhang Y, Spinar J, Cohen-Solal A, Iwashyna TJ, Mebazaa A; GREAT Network. Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J Heart Fail 2017;19:201. PubMed

Abualnaja S, Podder M, Hernandez AF, McMurray JJ, Starling RC, O’Connor CM, Califf RM, Armstrong PW, Ezekowitz JA.. Acute heart failure and atria fibrillation: insights from the acute study of clinical effectiveness of nesiritide in decompensated heart failure (ASCEND-HF) trial. J Am Heart Assoc 2015;4:e002092. PubMed PMC

Mendes FD, Atié J, Garcia MI, Gripp ED, Sousa AS, Feijó LA, Xavier SS.. Atrial fibrillation in decompensated heart failure: associated factors and in-hospital outcome. Arq Bras Cardiol 2014;103:315–322. PubMed PMC

Momomura S. Acute rate control in atrial fibrillation with left ventricular dysfunction. Circ J 2013;77:893–894.10.1253/circj.CJ-13-0289 PubMed DOI

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K.. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609–1678. PubMed

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975. PubMed

Arrigo M, Bettex D, Rudiger A.. Management of atrial fibrillation in critically ill patients. Crit Care Res Pract 2014;2014:840615. PubMed PMC

12-Czarnywojtek A, Płazińska MT, Zgorzalewicz-Stachowiak M, Woliński K, Stangierski A, Miechowicz I, Waligórska-Stachura J, Gut P, Królicki L, Zioncheck M, Ruchała M.. Dysfunction of the thyroid gland during amiodarone therapy: a study of 297 cases. Ther Clin Risk Manag 2016;12:505–513. PubMed PMC

Adachi T, Sato A, Baba M, Hiraya D, Hasegawa T, Kuroki K, Hoshi T, Aonuma K.. Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. Heart Vessels 2014;29:464–469. PubMed

Nikolaou NI, Koutouzis MJ, Christou A, Fournarakis GM, Patsilinakos SP, Rompola A, Maisel AS.. B-type natriuretic peptide blood levels identify patients with non-ST elevation acute coronary syndromes at high risk for complications during intravenous beta-blocker infusion. Acute Card Care 2011;13:129–135. PubMed

Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J 2013;77:908–916. PubMed

Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. Adv Ther 2014;31:426–439. PubMed PMC

Kobayashi S, Murakami W, Myoren T, Tateishi H, Okuda S, Doi M, Nao T, Wada Y, Matsuzaki M, Yano M.. A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. Cardiology 2014;127:105–113. PubMed

Ozaki T, Yamada T, Morita T, Furukawa Y, Tamaki S, Iwasaki Y, Kawasaki M, Kikuchi A, Kondou T, Sato Y.. Urgent control of rapid atrial fibrillation using landiolol in patients with acute decompensated heart failure with reduced or preserved left ventricular ejection fraction. Eur Heart J 2016; 37(Abstract Supplement):1319.

Kiuchi S, Aikawa H, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, Ikeda T.. Efficacy of intravenous administration of landiolol in patients with acute heart failure and supraventricular tachyarrhythmia. J Clin Med Res 2017;9:426–432. PubMed PMC

Wada Y, Aiba T, Tsujita Y, Itoh H, Wada M, Nakajima I, Ishibashi K, Okamura H, Miyamoto K, Noda T, Sugano Y, Kanzaki H, Anzai T, Kusano K, Yasuda S, Horie M, Ogawa H.. Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction. J Arrhythm 2016;32:82–88. PubMed PMC

Nitta D, Kinugawa K, Imamura T, Endo M, Amiya E, Inaba T, Maki H, Hatano M, Komuro I.. An experience of landiolol use for an advanced heart failure patient with severe hypotension. Int Heart J 2015;56:564–567. PubMed

Morisaki A, Hosono M, Sasaki Y, Hirai H, Sakaguchi M, Nakahira A, Seo H, Suehiro S.. Very-low-dose continuous drip infusion of landiolol hydrochloride for postoperative atrial tachyarrhythmia in patients with poor left ventricular function. Gen Thorac Cardiovasc Surg 2012;60:386–390. PubMed

Miwa Y, Ikeda T, Mera H, Miyakoshi M, Hoshida K, Yanagisawa R, Ishiguro H, Tsukada T, Abe A, Yusu S, Yoshino H.. Effects of landiolol, an ultra-short-acting beta1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J 2010;74:856–863. PubMed

Yoshima S. Concomitant administration of landiolol and dobutamine in acute heart failure syndrome with atrial tachyarrhythmia. Eur Heart J 2017; 38(Abstract Supplement):580.

Sezai A, Osaka S, Yaoita H, Ishii Y, Arimoto M, Hata H, Shiono M.. Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventricular Dysfunction (PLATON) trial. J Thorac Cardiovasc Surg 2015;150:957–964. PubMed

Fellahi JL, Heringlake M, Knotzer J, Fornier W, Cazenave L.. Guarracino F. Landiolol for managing atrial fibrillation in post-cardiac. Eur Heart J 2018;20(Suppl A):A4–A9. PubMed PMC